Loading...

APC anti-human HLA-A,B,C Antibody

Pricing & Availability
Clone
W6/32 (See other available formats)
Regulatory Status
RUO
Other Names
Major Histocompatibility Class I, MHC class I
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
W632_APC_072607
Human peripheral blood lymphocytes stained with W6/32 APC
  • W632_APC_072607
    Human peripheral blood lymphocytes stained with W6/32 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
311409 25 tests 110€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
311410 100 tests 233€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells. MHC class I molecules are involved in presentation of antigens to CD8+ T cells. They play an important role in cell-mediated immune responses and tumor surveillance.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Baboon, Cat, Cow, Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone W6/32 recognizes residues in the N terminus of the human ß2-microglobulin molecule21.

Additional reported applications (for the relevant formats) include: immunoprecipitaton2, Western blotting (non-reducing)3, immunohistochemical staining of acetone-fixed frozen tissue sections4,5, blocking6,7, inhibition of NK cell-mediated lysis10, and activation8,9. Clone W6/32 has been reported not to be suitable for immunohistochemistry on paraffin sections17. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 311428) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References
  1. Darrow TL, et al. 1989. J. Immunol. 142:3329.
  2. Stern P, et al. 1987. J. Immunol. 138:1088.
  3. Tran TM, et al. 2001. Immunogenetics 53:440.
  4. Barbatis C, et al. 1981. Gut 22:985.
  5. Ayyoub M, et al. 2004. Cancer Immunity 4:7.
  6. DeFelice M, et al. 1990. Cell. Immunol. 126:420.
  7. Fayen J, et al. 1998. Int. Immunol. 10:1347.
  8. Turco MC, et al. 1988. J. Immunol. 141:2275.
  9. Geppert TD, et al. 1989. J. Immunol. 142:3763.
  10. Wooden SL, et al. 2005. J. Immunol. 175:1383.
  11. Nagano M, et al. 2007. Blood 110:151.
  12. McLoughlin RM,et al.2008. J. Immunol. 181:1323. PubMed
  13. Takahara M, et al.2008. J. Leukoc. Biol. 83:742. PubMed
  14. Lunemann A, et al.2008. J. Immunol. 181:6170. PubMed
  15. Laing BJ, et al. 2010. J. Thorac Cardiovasc Surg. 139:1402. PubMed
  16. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  17. Vambutas A, et al. 2000. Clin. Diagn. Lab. Immun. 7:79.
  18. Coppieters KT, et al. 2012. J. Exp. Med. 209:51. (epitope)
  19. Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed
  20. Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed
  21. Shields MJ. Ribaudo RK. 1998. Tissue Antigens. 51(5):567-70. (epitope)
Product Citations
  1. Ho J, et al. 2016. PLoS Biol. 14:e2000117. PubMed
  2. Preece R, et al. 2020. Gene Ther. 451:27. PubMed
  3. Hoke ATK, et al. 2021. Cancer Res Commun. 1:127. PubMed
  4. Kemble S, et al. 2022. Blood Adv. 6:2932. PubMed
  5. Gerace D, et al. 2023. Cell Rep Med. 4:100879. PubMed
  6. Tunali G, et al. 2023. J Clin Invest. :. PubMed
  7. Sparbier CE, et al. 2023. Nat Cell Biol. 25:258. PubMed
  8. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  9. Yamaguchi S, et al. 2021. Eur J Immunol. 51:2306. PubMed
  10. Charles A, et al. 2021. Oncoimmunology. 10:1916243. PubMed
  11. Ferrari de Andrade L, et al. 2020. Cancer Immunol Res. 0.867361111. PubMed
  12. Zuo J, et al. 2011. J Virol. 85:1604. PubMed
  13. Foucras G, et al. 2011. J Immunol. 187:6564. PubMed
  14. Kaseke C, et al. 2021. Cell Reports. 36(2):109378. PubMed
  15. Choi J, et al. 2021. Cell Rep Methods. 1:100084. PubMed
  16. Rosskopf S, et al. 2016. Sci Rep. 6:31580. PubMed
  17. Hashimoto M, et al. 2015. J Immunol. 95: 4341 - 4350. PubMed
  18. Mitchell K, et al. 2018. J Exp Med. 215:1709. PubMed
  19. Heusinger E, et al. 2018. J Virol. 92:18. PubMed
  20. Kula T, et al. 2019. Cell. 178:1016. PubMed
  21. Zhuang X, et al. 2020. Front Immunol. 2.415972222. PubMed
  22. Madrid A, et al. 2012. J Virol. 86: 8693. PubMed
  23. Bachireddy P, et al. 2020. Sci Transl Med. :12. PubMed
  24. Bondarenko M, et al. 2021. Cancers (Basel). 13: . PubMed
  25. Ren J, et al. 2022. J Clin Invest. . PubMed
  26. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
  27. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
  28. Amabile A et al. 2016. Cell. 167(1):219-232 . PubMed
  29. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  30. Ng W, et al. 2021. Pharm Biol. 59:47:00. PubMed
  31. Rapiteanu R, et al. 2020. Eur Respir J. :55. PubMed
  32. Lian W, et al. 2022. J Immunol Res. 2022:3129765. PubMed
  33. Mandrup OA, et al. 2021. Commun Biol. 310:4. PubMed
  34. Shan X et al. 2017. eLife. 6 pii: e25306. PubMed
  35. Bradley S, et al. 2015. Cancer Immunol Res. 3:602. PubMed
  36. Hashimoto M, et al. 2016. J Immunol. 1832 - 1841. PubMed
  37. Burr ML, et al. 2019. Cancer Cell. 36:385. PubMed
  38. Amo L, et al. 2022. Front Immunol. 13:835527. PubMed
  39. Okita R, et al. 2021. Thorac Cancer. 12:775. PubMed
  40. Io S, et al. 2021. Cell Stem Cell. 28(6):1023-1039.e13. PubMed
  41. Croft N, et al. 2009. PLoS One. 5:e1000490. PubMed
  42. Usmani SM et al. 2019. Cell host & microbe. 25(1):73-86 . PubMed
  43. Slaine PD, et al. 2021. J Virol. 95:e00453. PubMed
  44. Bear AS, et al. 2021. Nat Commun. 12:4365. PubMed
  45. Lee JH, et al. 2020. Nat Commun. 11:1897. PubMed
  46. Yao C, et al. 2018. Autophagy. 1.854861111. PubMed
  47. Bagati A, et al. 2020. Cancer Cell. 39(1):54-67.e9. PubMed
  48. Sim MJW, et al. 2020. Proc Natl Acad Sci U S A. 117:12826. PubMed
  49. Dheilly E, et al. 2020. Cancer Cell. 37(5):674-689. PubMed
  50. Lee PC, et al. 2022. J Clin Invest. 132:. PubMed
  51. Rainho J, et al. 2015. J Virol. 89: 10625 - 10636. PubMed
  52. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  53. Alvino VV, et al. 2018. J Am Heart Assoc. 7:e006727. PubMed
  54. Joas S, et al. 2018. Nat Commun. 9:902. PubMed
  55. Joas S, et al. 2020. Cell Rep. 30:2261. PubMed
  56. Kimmel E, et al. 2011. Antiviral Res. 90:80. PubMed
  57. Saif J, et al. 2010. Arterioscler Thromb Vasc Biol. 30:1897. PubMed
RRID
AB_314879 (BioLegend Cat. No. 311409)
AB_314879 (BioLegend Cat. No. 311410)

Antigen Details

Structure
Ig superfamily
Distribution

All nucleated cells

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD8
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Barclay AN, et al. Eds. 1993. The Leukocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
3105 View all products for this Gene ID
UniProt
View information about HLA-A on UniProt.org

Other Formats

View All HLA-A,B,C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-human HLA-A,B,C W6/32 FC
FITC anti-human HLA-A,B,C W6/32 FC
PE anti-human HLA-A,B,C W6/32 FC
PE/Cyanine5 anti-human HLA-A,B,C W6/32 FC
Purified anti-human HLA-A,B,C W6/32 FC,Activ,Block,IHC-F,IP,WB
Alexa Fluor® 488 anti-human HLA-A,B,C W6/32 FC
Alexa Fluor® 647 anti-human HLA-A,B,C W6/32 FC
Pacific Blue™ anti-human HLA-A,B,C W6/32 FC
PerCP anti-human HLA-A,B,C W6/32 FC
APC/Cyanine7 anti-human HLA-A,B,C W6/32 FC
PerCP/Cyanine5.5 anti-human HLA-A,B,C W6/32 FC
Ultra-LEAF™ Purified anti-human HLA-A,B,C W6/32 FC,Activ,Block,IHC-F,IP,WB
PE/Cyanine7 anti-human HLA-A,B,C W6/32 FC
Brilliant Violet 510™ anti-human HLA-A,B,C W6/32 FC
Alexa Fluor® 700 anti-human HLA-A,B,C W6/32 FC
PE/Dazzle™ 594 anti-human HLA-A,B,C W6/32 FC
Biotin anti-human HLA-A,B,C W6/32 FC
Brilliant Violet 605™ anti-human HLA-A,B,C W6/32 FC
APC/Fire™ 750 anti-human HLA-A,B,C W6/32 FC
TotalSeq™-A0058 anti-human HLA-A,B,C W6/32 PG
TotalSeq™-C0058 anti-human HLA-A,B,C W6/32 PG
TotalSeq™-B0058 anti-human HLA-A,B,C W6/32 PG
Spark NIR™ 685 anti-human HLA-A,B,C W6/32 FC
TotalSeq™-D0058 anti-human HLA-A,B,C W6/32 PG
GMP Ultra-LEAF™ Purified anti-human HLA-A,B,C SF W6/32 FC
GMP Ultra-LEAF™ Biotin anti-human HLA-A,B,C SF W6/32 FC
Spark UV™ 387 anti-human HLA-A,B,C W6/32 FC
Spark Red™ 718 anti-human HLA-A,B,C (Flexi-Fluor™) W6/32 FC
Spark Blue™ 574 anti-human HLA-A,B,C (Flexi-Fluor™) W6/32 FC
Spark Blue™ 550 anti-human HLA-A,B,C (Flexi-Fluor™) W6/32 FC
Go To Top Version: 2    Revision Date: 01/16/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account